Sort
82,697 grants matching “vaccine development”
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers
$879,388Stephen Philip Schoenberger · La Jolla Institute For Immunology · U01 · FY2018 · DE
Integrated Services Core
$879,285William Paul Duprex · University Of Pittsburgh At Pittsburgh · UC7 · FY2024 · AI
Screening Complete TB Proteome for Protective Antigens
$879,258Alan Greener · Gene Therapy Systems, Inc. · R44 · FY2008 · AI
Impact of Immunotherapy on Viral Immunity in Humans
$879,190Raymond T Chung · Massachusetts General Hospital · U19 · FY2021 · AI
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
$879,161Beatrice H Hahn · University Of Pennsylvania · R37 · FY2024 · AI
High-throughput mapping of antigen specificity to B-cell-receptor sequence for characterizing antibody responses in HIV-vaccinated and infected individuals
$879,020Ivelin Georgiev · Vanderbilt University Medical Center · R01 · FY2020 · AI
Structure-Based Design of a Broadly Protective Group A Streptococcal Vaccine
$879,004James B. Dale · University Of Tennessee Health Sci Ctr · R01 · FY2018 · AI
Alphavirus Replicon Vaccines against Botulinum Neurotoxin
$878,891Robert A. Olmsted · Alphavax Human Vaccines, Inc. · U01 · FY2007 · AI
Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 Vaccine
$878,835Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2009 · AI
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
$878,832Stefanie N. Vogel · University Of Maryland Baltimore · R01 · FY2014 · AI
Mucosal Vaccination Against Dengue Virus Infection
$878,792Sujan Shresta · La Jolla Institute For Immunology · U01 · FY2010 · AI
Project 1: PREVENT Program Critical Path Project
$878,739Daniel Tuse · University Of Louisville · U19 · FY2016 · AI
Novel Immunoprophylaxes against Clostridium difficile Infection
$878,733Hanping Feng · University Of Maryland Baltimore · U19 · FY2014 · AI
The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination
$878,617John Ross Teijaro · Scripps Research Institute, The · R01 · FY2023 · AI
Project 2: Susceptibility of Lung Cancer Cells to SARS- CoV-2 Infection and Antibody-Mediated Neutralization
$878,495Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · U54 · FY2020 · CA
An adjuvant that promotes TH1/TH17 and CD8 T cells in a tuberculosis vaccine
$878,466Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · AI
A therapeutic vaccine for chronic hepatitis B
$878,409David R. Milich · Vlp Biotech, Inc. · R44 · FY2019 · AI
Modulation of Viral Antigen Presentation in the Lung
$878,401Anna Karolina Palucka · Jackson Laboratory · U19 · FY2020 · AI
The Danger Model 2: how tissues control Immunity
$878,217Polly C Matzinger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Novel Therapeutics for Neurotropic Alphaviruses
$878,113David J Miller · University Of Michigan At Ann Arbor · R01 · FY2011 · AI
Translational Geroscience Network
$878,093James L. Kirkland · Mayo Clinic Rochester · R33 · FY2019 · AG
Membrane protein effectors of pathogen interactions with host
$877,999Francesca M Marassi · Sanford Burnham Prebys Medical Discovery Institute · R35 · FY2018 · GM
Systems biological analyses of innate responses to vaccination
$877,945Bali Pulendran · Emory University · U19 · FY2012 · AI
In vivo CRISPR engineering of B cells to produce anti-HIV broadly neutralizing antibodies using novel nanoparticles
$877,927Jennifer Eileen Adair · Fred Hutchinson Cancer Center · R01 · FY2022 · AI
RNA: New Antimicrobial Strategies
$877,860Adrian Ferrã-D'amarã · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL